News
Important Only
Reuters14 hours ago
Software company Monday.com beats Q2 revenue estimates
Reuters14 hours ago
Biopharma firm Roivant's Q1 revenue declines, net loss widens to $273.9 mln
Reuters14 hours ago
Ad-tech firm Perion's Q2 adjusted EPS beats estimates
Reuters14 hours ago
Europe races to try to influence US position ahead of Trump-Putin talks
Reuters14 hours ago
Powerfleet Q1 revenue beats estimates; raises FY26 revenue guidance
The Motley Fool14 hours ago
Harvard Bioscience Tops Q2 Revenue Views
Other
Software company Monday.com beats Q2 revenue estimates
OverviewMonday.com Q2 revenue grows 27% yr/yr, beating analysts' expectationsReports GAAP operating loss, but non-GAAP operating income improvesCo adds record number of customers with over $100k in ARROutlookCompany expects Q3 revenue between $311 mln and $313 mlnmonday.com forecasts full-year r...Reuters
14 hours ago
Other
Biopharma firm Roivant's Q1 revenue declines, net loss widens to $273.9 mln
OverviewRoivant fiscal Q1 revenue declines significantly, reflecting increased R&D expensesCompany reports net loss from continuing operations of $273.9 mlnRoivant completed $1.5 bln share repurchase program, reducing shares by over 15%OutlookRoivant expects brepocitinib DM trial data in H2 2025...Reuters
14 hours ago
Other
Ad-tech firm Perion's Q2 adjusted EPS beats estimates
OverviewPerion Q2 2025 rev drops 5% yr/yr to $103 mlnAdjusted EPS and EBITDA beat analyst expectations, per LSEG dataCo repurchased 3.6 mln shares for $33.4 mln in Q2OutlookPerion reiterates FY 2025 revenue guidance of $430 mln to $450 mlnCompany expects FY 2025 adjusted EBITDA between $44 mln and $...Reuters
14 hours ago
Other
Europe races to try to influence US position ahead of Trump-Putin talks
BRUSSELS, Aug 11 (Reuters) - Polish Prime Minister Donald Tusk said that the U.S. had pledged to consult with Europe ahead of a summit with Russia's Vladimir Putin, as European ministers prepare for discussions amid fears Washington may dictate unfavourable peace terms to Ukraine.European Union ...Reuters
14 hours ago
Other
Powerfleet Q1 revenue beats estimates; raises FY26 revenue guidance
OverviewPowerfleet fiscal Q1 revenue rises 38% yr/yr, beating analyst expectations, per LSEG dataAdjusted EBITDA for fiscal Q1 increases 58%, reflecting margin expansionCo raises FY26 revenue guidance to $430-$440 mln, indicating growth confidenceOutlookPowerfleet raises FY26 revenue guidance to $43...Reuters
14 hours ago
Stocks
Harvard Bioscience Tops Q2 Revenue Views
Key PointsGAAP revenue of $20.5 million in Q2 2025 surpassed analyst expectations by 9.3%, despite a decline from the same period in 2024.Non-GAAP loss per share was $(0.01) in Q2 2025.Cash provided by operations (GAAP) improved sharply to $2.8 million in Q2 2025, up from an outflow in the prior-yea...The Motley Fool
14 hours ago
Economic Indicator
Brent retreats after failing to break above 200-DMA – Société Générale
Brent crude’s inability to hold above the key $71 mark is reviving bearish sentiment, with technicals pointing to deeper losses if support at $63 gives way, Société Générale's FX analysts note.Fxstreet
14 hours ago
Stocks
Compass Therapeutics Posts Wider Q2 Loss
Key PointsCompass Therapeutics posted a wider-than-expected GAAP loss per share of $(0.14) in the second quarter. as R&D spending climbed 47% to $16.4 million (GAAP) in the second quarter.No revenue was recorded, after $0.85 million (GAAP) in the prior-year period, reflecting the absence of licensin...The Motley Fool
14 hours ago
Commodities
Americas Gold Q2 revenue misses estimates on lower zinc, lead production and prices
OverviewAmericas Gold and Silver Q2 silver production up 36% yr/yrRevenue for Q2 falls 19%, missing analyst expectationsCo announces share consolidation and secures $100 mln loan facilityOutlookCompany expects commercial production at EC120 by end of 2025Company aims to leverage antimony as new reve...Reuters
14 hours ago
Other
Compass Therapeutics Q2 net loss widens to $19.9 mln
OverviewCompass Q2 net loss widens to $19.9 mln from $13.1 mln last yearCompany ends Q2 with $101 mln cash, runway into 2027Tovecimig shows fewer deaths than projected in Phase 2/3 studyOutlookCompany expects tovecimig secondary endpoint analysis in Q1 2026Compass plans CTX-8371 cohort expansions in...Reuters
14 hours ago
Other
Biogen And Stoke Therapeutics Announce First Patient Dosed In Phase 3 Emperor Study Of Zorevunersen
Aug 11 (Reuters) - Biogen Inc BIIB.O:BIOGEN AND STOKE THERAPEUTICS ANNOUNCE FIRST PATIENT DOSED IN PHASE 3 EMPEROR STUDY OF ZOREVUNERSEN, A POTENTIAL DISEASE-MODIFYING TREATMENT FOR DRAVET SYNDROMEReuters
14 hours ago
Other
Humacyte misses Q2 revenue estimates, net loss narrows
OverviewHumacyte Q2 revenue of $0.3 mln missed analyst expectations, per LSEG dataNet loss for Q2 narrows to $37.7 mln, but misses analyst estimates, per LSEG dataCo achieved significant progress in Symvess market launch with VAC and ECAT approvalsOutlookCompany plans to submit supplemental BLA in 2...Reuters
14 hours ago
Other
Harvard Bioscience Q2 revenue meet estimates
OverviewHarvard Bioscience Q2 2025 revenue in line with analyst expectations, per LSEG dataAdjusted EPS for Q2 meets analyst estimates, indicating stable performanceCompany signs credit amendment, extending refinance deadline to Dec 5, 2025OutlookHarvard Bioscience expects Q3 2025 revenue between $1...Reuters
14 hours ago
